**Novel Melatonin, Estrogen, and Progesterone Hormone Therapy Demonstrates Anti-Cancer Actions in MCF-7 and MDA-MB-231 Breast Cancer Cells**

Mahmud Hasan1, Erin Browne1, Laura Guarinoni1, Travis Darveau1, Katherine Hilton1 and Paula A Witt-Enderby1,2

1Division of Pharmaceutical, Administrative and Social Sciences, Graduate School of Pharmaceutical Sciences, School of Pharmacy, Duquesne University, Pittsburgh, PA, USA.

2UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

**ABSTRACT:** A novel melatonin, estrogen, and progesterone hormone therapy was developed as a safe bio-identical alternative hormone therapy for menopausal women based on the Women’s Health Initiative findings that PremPro™ increased breast cancer risk and mortality of all types of breast cancer in postmenopausal women. For HER2 breast cancer, melatonin, estrogen, and progesterone inhibited proliferation and migration of both breast cancer lines. Inhibition of MEK1/2 and 5 using PD98059 and BIX02199, respectively, inhibited proliferation and migration in MDA-MB-231 cells and proliferation in MCF-7 cells; however, when combined with melatonin, estrogen, and progesterone, BIX02199 blocked melatonin, estrogen, and progesterone-mediated inhibition of migration in MCF-7 cells and induced Eif-5. For MDA-MB-231 cells, BIX02199 combined with melatonin, estrogen, and progesterone inhibited proliferation and increased pERK1/2 and β1-INTEGRIN; levels of pERK5 remained low/nearly absent in both breast cancer lines. These findings demonstrate novel anti-cancer actions of melatonin, estrogen, and progesterone in ER+ and triple negative breast cancer cells through intricate MEK1/2- and MEKS-associated signaling cascades that favor anti-proliferation and anti-migration.

**KEYWORDS:** Melatonin receptors, breast cancer, melatonin, estrogen, progesterone, PremPro, MCF-7, MDA-MB-231, ERK1/2, ERK5, NF-κB, RUNX2, β1-INTEGRIN, RANKL, Eif-5

**Introduction**

A novel melatonin, estrogen, and progesterone hormone therapy (MEMP HT) was developed as an alternative bio-identical hormone therapy (HT) for menopausal women to relieve menopausal symptoms without increasing the risk of breast cancer (BC) shown to occur with conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA). The MEMP HT, which contains 5 mg melatonin (M), 0.5 mg estradiol (E/E2), and half the recommended dose of progesterone (50 vs 100 mg; P/P4), decreased tumor incidence, delayed tumor onset, and protected the uterus in HER2/neu breast cancer in postmenopausal women. For HER2 breast cancer, melatonin, estrogen, and progesterone inhibited proliferation and migration of both breast cancer lines. Inhibition of MEK1/2 and 5 using PD98059 and BIX02199, respectively, inhibited proliferation and migration in MDA-MB-231 cells and proliferation in MCF-7 cells; however, when combined with melatonin, estrogen, and progesterone, BIX02199 blocked melatonin, estrogen, and progesterone-mediated inhibition of migration in MCF-7 cells and induced Eif-5. For MDA-MB-231 cells, BIX02199 combined with melatonin, estrogen, and progesterone inhibited proliferation and increased pERK1/2 and β1-INTEGRIN; levels of pERK5 remained low/nearly absent in both breast cancer lines. These findings demonstrate novel anti-cancer actions of melatonin, estrogen, and progesterone in ER+ and triple negative breast cancer cells through intricate MEK1/2- and MEKS-associated signaling cascades that favor anti-proliferation and anti-migration.

**Materials and Methods**

**Radioligand binding**

Melatonin receptor expression was assessed by total 2-[125I]-iodomelatonin binding described previously...
Breast Cancer: Basic and Clinical Research

Estrogen receptor (ER) expression was assessed by total \([\text{\[^{3}H\]}	ext{-estradiol binding}}\). Saturation and total binding analyses were conducted on whole cell lysates prepared from MCF-7 or MDA-MB-231 grown to confluence on 10 cm plates, then washed with 5 mL of phosphate-buffered saline (PBS), lifted into buffer (10 mM KPO \(_4\), 1 mM ethylenediaminetetraacetic acid [EDTA], pH 7.4), pelleted by centrifugation (277 g, 5 minutes), and then resuspended in Tris-HCl buffer (1 mL; 50 mM, pH 7.4). To assess melatonin receptor expression, cells were added to tubes containing 2-\([\text{\[^{125}I\]}	ext{-iodomelatonin (2200 Ci/mmol, Perkin Elmer, Waltham, MA, USA; 0-500 pM for saturation analysis and 500 pM for total binding assays) in the absence (total binding) or presence (non-specific binding) of 1 µM melatonin (Sigma, St. Louis, MO, USA). To assess ER expression, cells were added to tubes containing 3 nM \([\text{\[^{3}H\]}	ext{-estradiol (94 Ci/mmol, Perkin Elmer) in the absence (total binding) or presence (non-specific binding) of 1 µM tamoxifen (Millipore Sigma, Burlington, MA, USA). Cells were incubated for 1 hour at room temperature and then terminated by the addition of ice-cold Tris-HCl solution (50 mM) and rapid filtration over glass-fiber filters (0.22 µm; Schleicher & Schuell, Keene, NH, USA) pre-soaked in 0.5% polyethylenimine solution (w/v; Sigma). Each filter was washed twice with 5 mL of cold buffer. Filters were placed in glass vials (2-\([\text{\[^{125}I\]}	ext{-iodomelatonin}) or vials containing scintillation fluid (\([\text{\[^{3}H\]}	ext{-estradiol}) and then counted in a gamma counter or scintillation counter, respectively. Total protein measurements were made on cell lysates using the Pierce BCA protein assay. Saturation binding analysis was already performed for \([\text{\[^{3}H\]}	ext{-estradiol binding in MCF-7 cells as described}\(^{24}\) and not performed in MDA-MB-231 cells due to a lack of \([\text{\[^{3}H\]}	ext{-estradiol expression}}\) (Figure 1A).

**Cell proliferation**

MCF-7 and MDA-MB-231 cell lines, obtained from American Type Culture Collection (Manassas, VA, USA), were cultured in DMEM:F12 medium (Thermo Scientific, Pittsburgh, PA, USA) containing 10% fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA, USA) and 1% penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO, USA) at 37°C in a humidified atmosphere with 5% CO\(_2\). Cells were plated in 24-well plates (3000 cells/well) and cultured in DMEM:F12 supplemented with 10% FBS and 1% penicillin/streptomycin for 24 hours prior to the addition of the treatments (vehicle, 50 pM E\(_2\), 10 nM P\(_4\), or 50 pM E\(_2\)+10 nM P\(_4\)+1 nM Mel). After 24 hours, cells were counted by trypan blue exclusion. Concentration effects of E\(_2\), P\(_4\), and melatonin individually (1 pM, 1 nM, 100 nM, 1 µM, 10 µM) were also tested to determine how each component of MEMP HT affected MCF-7 and MDA-MB-231 cell proliferation. For the inhibitor studies, cells were exposed to 10 µM BIX02189 (Santa Cruz Biotechnology, Dallas, TX, USA) or 10 µM PD98059 (Santa Cruz Biotechnology) alone or in combination with 50 pM E\(_2\) (Sigma), 10 nM P\(_4\) (Sigma), and 1 nM Mel (Sigma). Inhibitors were added 15 minutes before the addition of MEMP HT. The in vitro concentrations of E\(_2\), P\(_4\), and melatonin used in this study were based on serum levels of MEMP HT achieved in *...*
mice following consumption of 0.5 mg E2 and 50 mg P4 in the diet and 15 mg/L melatonin in water at night. These doses of melatonin, E2, and P4 demonstrated anti-cancer actions in female mice.

Migration or “scratch” assay
To investigate the effect of the various treatments on cell migration, the wound healing, or “scratch,” assay was employed as described. Confluent cells from one 10 cm² plate were lifted into 12 mL medium and were seeded into 24-well plates (0.5 mL/well) and grown overnight. A cell border was created using a 10 µL pipette tip that was dragged across the bottom of each well. Next, the medium from each well was removed, cells were washed once with PBS, and then cells were re-fed with fresh medium (0.5 mL) containing the treatments described previously. Images of cell borders (Figures 2D and 3D) were taken at 0 hour and after 24 hours exposure to the treatments with an EVOS digital inverted fluorescence microscope (magnification 10×) under transmittance light. The wound area was quantified by measuring the bandwidth of the scratch at 0 hour (baseline) and following 24 hours of treatments as described. A more negative number, indicated by a decrease in border width, would be indicative of a more invasive phenotype, whereas a more positive number, indicated by a wider border width, would be indicative of a less invasive phenotype.

Western blot
To assess potential intracellular targets underlying MEMP HT action in MCF-7 and MDA-MB-231 cells, western blot analysis was performed analyzing pERK1/2, pERK5, NF-κB, RUNX2, β1-INTEGRIN, Elf-5, and RANKL levels. MCF-7 and MDA-MB-231 cells were exposed to the treatments described previously for 24 hours and then scraped into Laemmli sample buffer containing β-mercaptoethanol and stored at -20°C until use. Equal amounts of each sample (25 µL) and 8 µL of molecular weight marker (Precision Plus ProteinTM, CAT# 161-0373, BioRad, Hercules, CA, USA) were loaded onto 10% SDS-PAGE (sodium dodecyl sulfate–polyacrylamide gel electrophoresis) gels. Proteins were transferred to nitrocellulose membranes and then incubated in blocking buffer (LI-COR Biosciences, Lincoln, NE, USA) for 30 minutes at room temperature. Next, membranes were incubated with primary antibodies at 4°C overnight followed by washing (4×) and incubation with secondary antibodies for 15 minutes at room temperature. Primary antibodies included rabbit anti-phospho-ERK1/2 (1:1000, Cell Signaling, Danvers, MA, USA), rabbit anti-phospho-ERK5 (T218/Y220; 1:1000, Cell Signaling), rabbit anti-NF-κB (p52; sc-298; 1:1000, Santa Cruz Biotechnology), rabbit anti-RUNX2 (sc-8978; 1:1000, Santa Cruz Biotechnology), rabbit anti-integrin β1 (M-106; sc-9073; 1:1000, Santa Cruz Biotechnology), rabbit anti-RANKL (sc-9073; 1:1000, Santa Cruz Biotechnology), rabbit
anti-Elf-5 (ab104410; 1:500; Abcam, Cambridge, MA, USA), and mouse anti-β-actin (926-42212, LI-COR Biosciences). Secondary antibodies included goat anti-mouse (1:20000; LI-COR Biosciences; IR680LT dye) or goat anti-rabbit (1:20000, LI-COR Biosciences; IR800CW dye). Protein bands were analyzed using fluorescent microscopy detection at 700 (β-actin) and 800 (all other proteins) channels on an Odyssey Infrared Imaging System. Proteins were normalized by β-actin to control for protein loading.

**Statistical analysis**

All statistical analyses were performed using GraphPad Prism (version 6; GraphPad Software, La Jolla, CA, USA). Each bar graph represents the mean ± SEM (standard error of the mean) from 3 independent studies. Data were analyzed by one-way analysis of variance (ANOVA) followed by Newman-Keuls’ multiple comparisons test and significance was defined as P < .05.

**Results**

**Effect of E2, P4, and melatonin on cell proliferation and migration**

MCF-7 cells, ER+/PR+ epithelial BC cells that also contain melatonin receptors, were exposed to each of the hormones (E2, P4, melatonin) to determine their effects on cell proliferation. As shown in Figure 1, MCF-7 cells expressed ERs at a level of 8.6 pmol/mg protein (Figure 1A) with an affinity (Kd) of 2.2 nM,24 and melatonin receptors at a level of 20.55 fmol/mg protein (Figure 1B) and affinity (Kd) of 13 pM (data not shown). A concentration-dependent stimulatory effect of E2 occurred on MCF-7 cell proliferation, whereas a concentration-dependent inhibitory effect of melatonin was observed (Figure 1C). P4 also increased MCF-7 cell proliferation compared with the vehicle (Figure 1C). MDA-MB-231, ER-/PR-/HER2-epithelial BC cells, expressed melatonin receptors, were exposed to each of the hormones (E2, P4, melatonin) to determine their effects on cell proliferation, whereas a concentration-dependent inhibitory effect of melatonin was observed (Figure 1C). P4 also increased MCF-7 cell proliferation compared with the vehicle (Figure 1C). MDA-MB-231, ER-/PR-/HER2-epithelial BC cells, expressed melatonin receptors at a level of 60.09 fmol/mg protein (Figure 1B) and affinity (Kd) of 1.7 nM (data not shown). No [3H]-estradiol binding sites were detected in MDA-MB-231 cells (Figure 1A) and no concentration-dependent actions of E2, P4, or melatonin on proliferation in MDA-MB-231 cells were observed (Figure 1D).

**Effect of MEMP HT, MEK1/2, and MEK5 on MCF-7 cell proliferation and migration**

MEMP HT decreased MCF-7 cell proliferation (Figure 2A) and migration (Figure 2C and D) compared with the vehicle. To further clarify the role of MEK1/2 and MEK5 on MEMP HT-mediated breast cancer protection, MCF-7 cells were exposed to MEMP HT in the presence or absence of MEK1/2 or 5 inhibitors using PD98059 or BIX02189 alone. Exposure to PD98059 or BIX02189 alone decreased MCF-7 cell proliferation, which was without further effect when combined with MEMP HT (Figure 2B). For migration, both PD98059 and BIX02189 alone were without effect and similar to the vehicle; however, when combined with MEMP HT (Figure 2C and D), BIX02189 but not PD98059 blocked MEMP HT’s effect on cell migration.

**Effect of MEMP HT, MEK1/2, and MEK5 on MDA-MB-231 cell proliferation and migration**

MEMP HT decreased MDA-MB-231 cell proliferation (Figure 3A) and migration (Figure 3C and D) compared with the vehicle. PD98059 and BIX02189 alone decreased cell proliferation compared with the vehicle (Figure 3B). The addition of PD98059, but not BIX02189, with MEMP HT, further decreased MDA-MB-231 proliferation (Figure 3B). With respect to migration, MEMP HT alone, PD98059 alone, and BIX02189 alone decreased cell migration compared with the vehicle; however, when combined with MEMP, no further decreases or blockade occurred (Figure 3C and D).

**Effect of MEMP HT on pERK1/2, pERK5, NF-κB, β1-INTEGRIN, Elf-5, and RANKL in MCF-7 cells**

As shown in Figure 4, MEMP HT alone increased pERK5 (Figure 4B) compared with the vehicle with no other effects observed for the other proteins. Acute (1 hour) or chronic (24hours) exposure to PD98059 decreased pErk1/2 levels as expected (Figure 4A and inset). PD98059 combined with MEMP HT decreased pERK5 and increased β1-INTEGRIN vs MEMP HT alone; β1-INTEGRIN levels also increased vs all other groups tested (Figure 4D). BIX022189 given alone for 1 hour (Figure 4B inset) or 24hours (Figure 4B) trended toward a decrease in pERK5 and increased NF-κb (Figure 4C) with no other effects occurring on the other proteins. When BIX02189 was combined with MEMP HT, pERK5 levels decreased compared with vehicle (Figure 4B) and BIX02189-mediated increases in NF-κb were attenuated (Figure 4C). No effects occurred for Elf-5 (Figure 4E) and RANKL (Figure 4F) regarding any treatments. Representative band images were shown in Table 1. RUNX2 was not tested because this protein is not expressed in MCF-7 cells.11

**Effect of MEMP HT on pERK1/2, pERK5, NF-κB, RUNX2, β1-INTEGRIN, and Elf-5 expression in MDA-MB-231 cells**

As shown in Figure 5, MEMP HT was without effect on any of the proteins analyzed when compared with the vehicle; however, effects were observed when combined with MEK1/2 or MEK5 inhibitors. Acute (1 hour) exposure to PD98059 reduced pERK1/2 vs vehicle (Figure 5A inset); however, when given chronically for 24hours, levels of pERK1/2 increased...
and were similar to vehicle (Figure 5), and levels of pERK5 (Figure 5B) and RUNX2 (Figure 5G) also increased vs vehicle. BIX029189 alone (1 hour exposure) decreased pERK5 (Figure 5B inset); however, levels increased and were similar to the vehicle when given chronically for 24 hours (Figure 5B). PD98059 combined with MEMP increased pERK1/2 vs BIX02189 alone and MEMP alone (Figure 5A) and increased β1-INTEGRIN vs vehicle, PD98059 alone, and MEMP alone (Figure 5D). MEMP combined with PD98059 also decreased pERK5 (Figure 5B) and RUNX2 (Figure 5G) induced by PD98059 alone. BIX02189 alone (24 hours) was without effect on any of the proteins examined; however, when BIX02189 was combined with MEMP, levels of pERK1/2 (Figure 5A), β1-INTEGRIN (Figure 5D), and Elf-5 (Figure 5E) increased vs vehicle, BIX02189 alone, and MEMP alone. No effects occurred for RANKL regarding any treatments (Figure 5F), and representative band images can be found in Table 2.

Discussion
The Women’s Health Initiative study on PremPro in post-menopausal women demonstrated that BC risk and mortality increased for all types of BC.1,2,25 The BC risk did not increase with the estrogen-only HT, Premarin, which suggested that the progestin, MPA, in PremPro, was involved.26,27 In response to these findings, a novel MEMP HT containing bio-identical hormones (5 mg melatonin, 0.5 mg E2, 50 mg P4) was developed with the dose of progesterone halved to decrease the development of BC that was potentially associated with progestin exposure. The MEMP HT demonstrated anti-cancer and uteroprotective actions in HER2/neu female mice,3 which was associated with a modulation of progesterone receptor A (PRA) (producing a higher PrA to PrB ratios) as well as Mek1/2- and Mek5-associated proteins like Runx2, NF-κB, Rankl, Elf-5, and β1-integrin. These effects of MEMP HT in neu female mice were dependent upon age (young, 3 months vs old, 1 year) and tissue (non-tumor mammary vs tumor).3,10 Although MEMP HT demonstrated anti-cancer actions against HER2 BC, the effect of and mechanisms underlying MEMP HT actions on ER+ and TNBC are not known and formed the basis for the present study.

In MCF-7 and MDA-MB-231 BC cells, MEMP HT decreased proliferation and migration, which is consistent with what was found for HER2/neu mammary cancer in female mice.3 Melatonin decreased the invasiveness of HER2-positive SKBR-3 cells and inhibited lung metastasis in orthotopic HER2-positive BC xenografts.28 The melatonin component of MEMP HT is more than likely contributing to these anti-proliferative and anti-migratory actions because melatonin is widely known for its anti-cancer actions in numerous studies as reported in BC research.4,20 Also, melatonin given to athymic “nude” mice transplanted with MDA-MB-231 cells demonstrated a reduction in tumor cell proliferation, tumor growth, and angiogenesis compared with animals given vehicle.29 Melatonin also has been shown to inhibit proliferation and metastatic properties of tumor cells grown in culture30-33 and
counteract estrogen-induced invasiveness of MCF-7 cells possibly through melatonin-induced ERα down-regulation. Melatonin decreased viability and migration in MDA-MB-231 cells. These findings suggest that melatonin may be working to decrease proliferation and migration through its own signaling cascades (e.g., MAPKs) but may also be countering the pro-stimulatory actions of E2 and P4 on MAPK pathways as shown.

These anti-cancer actions of MEMP HT may be attributed to the melatonin component working through melatonin receptors in both BC lines, particularly MT1, as demonstrated in MCF-7 cells. Melatonin, acting through melatonin receptors, also prevented tumor growth in an MCF-7 xenograft model. Melatonin receptor expression also demonstrates a strong correlation with TNBC metastases and mortality where tumors that did not express MT1 melatonin receptors had a significantly higher hazard ratio for disease progression, shorter progression-free survival, and disease-related death compared with those that expressed MT1 melatonin receptors.

Although melatonin receptor expression was 3 times higher for MDA-MB-231 cells compared with MCF-7 cells, melatonin inhibited MCF-7 proliferation but was without effect in MDA-MB-231 cells. These variable effects of melatonin in MDA-MB-231 cells have been demonstrated previously and may be due to other variables within the BC cells like intracellular signaling networks (e.g., MAPKs) that influence cell proliferation and migration. For example, MCF-7 cells are luminal type A and so they express ERs and PRs but not HER2, whereas MDA-MB-231 cells are triple negative devoid of ERs, PRs, and HER2. MDA-MB-231 cells also express higher basal levels of pERK1/2 compared with MCF-7 cells. These intracellular differences may underlie, in part,
Table 1. Representative protein band images of pERK1/2, pERK5, nuclear factor NF-kappa-B, beta 1 integrin, Elf-5, and RANKL in MCF-7 cells.

| Protein          | Vehicle | BIX02189 | PD98059 |
|------------------|---------|----------|---------|
| pERK1/2          | ![Image](image1.png) | ![Image](image2.png) | ![Image](image3.png) |
| pERK5            | ![Image](image4.png) | ![Image](image5.png) | ![Image](image6.png) |
| Elf-5            | ![Image](image7.png) | ![Image](image8.png) | ![Image](image9.png) |
| RANKL            | ![Image](image10.png) | ![Image](image11.png) | ![Image](image12.png) |
| Beta-actin       | ![Image](image13.png) | ![Image](image14.png) | ![Image](image15.png) |

| Protein          | MEMP HT | MEMP HT + BIX02189 | MEMP HT + PD98059 |
|------------------|---------|--------------------|-------------------|
| pERK1/2          | ![Image](image16.png) | ![Image](image17.png) | ![Image](image18.png) |
| pERK5            | ![Image](image19.png) | ![Image](image20.png) | ![Image](image21.png) |
| Elf-5            | ![Image](image22.png) | ![Image](image23.png) | ![Image](image24.png) |
| RANKL            | ![Image](image25.png) | ![Image](image26.png) | ![Image](image27.png) |
| Beta-actin       | ![Image](image28.png) | ![Image](image29.png) | ![Image](image30.png) |

| Protein          | Vehicle | MEMP HT | BIX02189 |
|------------------|---------|---------|----------|
| Nuclear factor NF-kappa-B | ![Image](image31.png) | ![Image](image32.png) | ![Image](image33.png) |
| Beta-actin       | ![Image](image34.png) | ![Image](image35.png) | ![Image](image36.png) |

| Protein          | MEMP HT + PD98059 | MEMP HT + BIX02189 | PD98059 |
|------------------|-------------------|--------------------|---------|
| Nuclear factor NF-kappa-B | ![Image](image37.png) | ![Image](image38.png) | ![Image](image39.png) |
| Beta-actin       | ![Image](image40.png) | ![Image](image41.png) | ![Image](image42.png) |

| Protein          | Vehicle | BIX02189 | PD98059 |
|------------------|---------|----------|---------|
| Beta 1 integrin  | ![Image](image43.png) | ![Image](image44.png) | ![Image](image45.png) |
| Beta-actin       | ![Image](image46.png) | ![Image](image47.png) | ![Image](image48.png) |

| Protein          | MEMP HT | MEMP HT + BIX02189 | MEMP HT + PD98059 |
|------------------|---------|--------------------|-------------------|
| Beta 1 integrin  | ![Image](image49.png) | ![Image](image50.png) | ![Image](image51.png) |
| Beta-actin       | ![Image](image52.png) | ![Image](image53.png) | ![Image](image54.png) |

Abbreviation: MEMP HT, melatonin, estrogen, and progesterone hormone therapy. Each protein band is representative of 3 independent experiments. Beta-actin bands were used as the loading control.
Breast Cancer: Basic and Clinical Research

their BC characteristics where MCF-7 cells are less proliferative and invasive than MDA-MB-231 cells indicated by low Ki67 levels in MCF-7 compared with MDA-MB-231.46

Melatonin combined with E2 and P4 as in MEMP HT inhibited MDA-MB-231 cell proliferation and migration suggesting that melatonin may be working in concert with E2 and P4 through melatonin receptor-independent pathways (ie, anti-oxidant, free-radical scavenging) and/or through melatonin-mediated anti-oxidant actions on the mitochondria as shown previously.23,48,49 In MCF-7 cells, the presence of ERs and melatonin receptors may have contributed to the anti-proliferative and anti-migratory actions of MEMP HT through reciprocal modulation to enhance melatonin receptor function and decrease ER function. The melatonin contained within MEMP HT may have decreased the pro-stimulatory actions of E2 (via down-regulation of ERα) as shown,35,36 while the E2 contained within MEMP HT may have increased melatonin receptor activity in MCF-7 cells increasing its response to melatonin49 and, therefore, MEMP HT’s anti-cancer actions in MCF-7 cells.

Elucidation of the mechanisms underlying MEMP HT effects in MCF-7 and MDA-MB-231 cell proliferation and migration is complicated and far from clear; however, most of the protein expression changes are induced by MEMP HT support anti-cancer actions and involvement of MAPK pathways. In MCF-7 cells, MEMP HT-mediated decreases in proliferation and migration (regardless of treatment) were associated with low pERK1/2; however, treatment-dependent effects were observed for pERK5, β1-INTEGRIN, Elf-5, RANKL, and RUNX2. High ERK1/2 levels are shown to be linked with good BC disease outcomes.51,52 Low pERK5 is associated with anti-proliferative properties because high ERK5 is associated with pro-survival properties of cells.13,14 High Elf-5 is involved with epithelial-to-mesenchymal transition decreasing invasiveness12 and motility.53 High β1-INTEGRIN is associated with increased cell-to-cell contact, less transformation, and less aggressive invasive phenotype. High RUNX2

Figure 5. Treatment effects on pERK1/2, pERK5, NF-κB, β1-INTEGRIN, Elf-5, RANKL, and RUNX2 expression in MDA-MB-231 cells. MDA-MB-231 cells were exposed to vehicle or MEMP HT for 24 hours and its effects on pERK1/2 (A), pERK5 (B), NF-κB (C), β1-INTEGRIN (D), Elf-5 (E), RANKL (F), or RUNX2 (G) expression in MDA-MB-231 cells by western blot analysis. The MEK1/2 inhibitor (10 µM PD98059) or the MEK5 inhibitor (10 µM BIX02189) was added to the treatments. Treatment groups are denoted on the x-axis and protein expression (normalized by β-actin) on the y-axis. Data were analyzed by one-way ANOVA followed by Newman-Keuls’ post hoc t-test where significance was defined as P < .05; a = P < .05 vs vehicle; b = P < .05 vs 10 µM BIX02189; c = P < .05 vs 10 µM PD98059; d = P < .05 vs MEMP HT; e = P < .05 vs MEMP HT + 10 µM BIX02189. Each bar represents the mean ± SEM from 3 independent experiments (please see Table 2 for band images). ANOVA indicates analysis of variance; MEMP HT, melatonin, estrogen, and progesterone hormone therapy; SEM, standard error of the mean.
Hasan et al

in MDA-MB-231 cells is not clear because high RUNX2 is associated with invasiveness\textsuperscript{11} and poor prognosis\textsuperscript{54}; however, given the findings that RUNX2 lay downstream of MEK5 and that pERK5 is low following MEMP HT exposure suggests that RUNX2 effects are negligible.

Table 2. Representative protein band images of pERK1/2, pERK5, nuclear factor NF-kappa-B, beta 1 integrin, Elf-5, RANKL, and RUNX2 in MDA-MB-231 cells.

| Protein                | BIX02189 | MEMP HT | PD98059 |
|------------------------|----------|---------|---------|
| pERK1/2                |          |         |         |
| pERK5                  |          |         |         |
| Nuclear factor NF-kappa-B |        |         |         |
| RUNX2                  |          |         |         |
| Beta-actin             |          |         |         |

| Protein                | MEMP HT + PD98059 | MEMP HT + BIX02189 | PD98059 |
|------------------------|-------------------|---------------------|---------|
| pERK1/2                |                   |                     |         |
| pERK5                  |                   |                     |         |
| Nuclear factor NF-kappa-B |               |                     |         |
| RUNX2                  |                   |                     |         |
| Beta-actin             |                   |                     |         |

| Protein                | Vehicle | BIX02189 | PD98059 |
|------------------------|---------|----------|---------|
| Beta 1 integrin        |         |          |         |
| Elf-5                  |         |          |         |
| RANKL                  |         |          |         |
| Beta-actin             |         |          |         |

| Protein                | MEMP HT | MEMP HT + BIX02189 | MEMP HT + PD98059 |
|------------------------|---------|---------------------|-------------------|
| Beta 1 integrin        |         |                     |                   |
| Elf-5                  |         |                     |                   |
| RANKL                  |         |                     |                   |
| Beta-actin             |         |                     |                   |

Abbreviation: MEMP HT, melatonin, estrogen, and progesterone hormone therapy.
Each protein band is representative of 3 independent experiments. Beta-actin bands were used as the loading control.

The melatonin component within MEMP HT may be producing anti-proliferative and anti-migratory actions via melatonin’s actions on MAPK pathways, which has been demonstrated in myriad studies, including in cancer cells.\textsuperscript{31,55–60} Although it is widely reported that MAPKs function in cancer,
how they function in cancer is not clear because the studies are mixed with respect to ERK1/2 expression and their association with BC.14,51,52,61 This may be due to the fact that intracellular localization of pERK1/2 (ie, cytosolic vs nuclear) was not accounted for in these studies, which is important considering that pERK1/2 (nuclear) is pro-proliferative while pERK1/2 (cytosolic) is pro-differentiation.62 Because it has been demonstrated that estrogen increases nuclear localization of ERK1/2 in MCF-7 cells,37 then, perhaps, melatonin is counteracting the E2-mediated increases in pERK1/2 translocation to the nucleus decreasing cell proliferation. Melatonin in other cell lines has been shown to retain pERK1/2 in the cytoplasm and regulate differentiation processes.63,64 Studies examining pERK1/2 (nuclear) vs (cytosolic) following MEMP HT exposure should be tested in future studies in vivo and in vitro.

In MCF-7 cells, PD98059 decreased MEMP-mediated increases in pERK5 and increased β1-INTEGRIN. These findings suggest that MEMP HT may be working through MEK1/2, MEK5, and β1-INTEGRIN to decrease the epithelial-to-mesenchymal transition12 reducing BC cell motility53 and also through β1-INTEGRIN to increase cell-to-cell contact and lessen migration in MCF-7 cells.40,65 Although reports on β1-INTEGRIN’s role in cancer are mixed with respect to how adhesion proteins function in tumor transformation, aggressiveness, and metastases,15,40,65-67 estrogens have been demonstrated to down-regulate68 and melatonin up-regulate68 adhesion proteins like E-cadherin and β1-integrin. Perhaps an interplay between E2 and melatonin in the MEMP HT occurred where melatonin counteracted E2-mediated decreases in β1-INTEGRIN in MCF-7 cells increasing β1-INTEGRIN levels resulting in greater cell-to-cell contact and less migration.

Although MEMP HT alone did not affect NF-κB, MEMP HT combined with BIX02189 decreased levels induced by BIX02190 alone. This suggests that MEMP HT produces inhibitory actions on NF-κB in MCF-7 cells through MEK5, which is consistent with other reports. For example, low NF-κB levels are associated with BC protection,69,70 high levels with increases in BC,18,70 tumor resistance to chemotherapy,69,71 conversion of ER(+) tumors to ER(−),72 and MEK1/2/5-mediated modulation of its expression.18,19

The MEMP HT combined with PD98059 produced greater effects in MDA-MB-231 cells compared with MCF-7 cells, which may be attributed to differences in intracellular signaling mechanisms (Figure 6) especially in MEK1/2-associated coupling to downstream proteins, to MEK5, or to having lower endogenous basal levels of pERK1/2 compared with MCF-7.24 For example, acute (1 hour) exposure to...
PD98059 inhibited pERK1/2 levels in both BC lines; however, how they responded to chronic (24 hours) inhibition by PD98059 or BIX02189 differed. For example, acute (1 hour) and chronic (24 hours) exposure to PD98059 decreased pERK1/2 levels in MCF-7. Interestingly, this same 24 hours exposure to PD98059 also decreased pERK5 levels suggesting that some form of MEK1/2-mediated cross-modulation on MEK5 occurred in MCF-7 cells (Figure 6A). For MDA-MB-231 cells, acute (1 hour) exposure to PD98059 decreased pERK1/2 levels, but following 24 hours exposure, levels of pERK1/2 and pERK5 increased. These findings suggest that homologous up-regulation of MEK1/2-associated pathways occurred affecting MEK5-associated signaling proteins like pERK5 (Figure 6B). These cross-modulatory pathways between MEK1/2 and 5, unique to each BC cell line, may also explain how BIX02189 but not PD98059 blocked MEMP-mediated inhibition of migration in MCF-7 and not in MDA-MB-231 cells. Future studies exploring these relationships should be examined in vivo.

Conclusions

The findings from this study demonstrate that novel MEMP HT produced anti-cancer actions in ER(+) and TNBC. This study also demonstrates that MEMP HT works through MEK1/2- and MEK-5-dependent intracellular signaling cascades uniquely in each BC line resulting in the modulation of key intracellular signaling proteins (i.e., pERK1/2, pERK5, NF-κB, β1-integrin) in MCF-7 cells (Figure 6A) and pERK1/2, pERK5, RUNX2, Elf-5, and β1-INTEGRIN in MDA-MB-231 cells (Figure 6B). The MEMP HT continues to demonstrate anti-cancer actions against myriad BCs, including HER2, ER(+), and TNBC (present study) providing further support for its use in menopausal women to relieve them of their menopausal symptoms without increasing their risk of BC. Future studies assessing MEMP HT’s actions against ER(+) and TNBC in vivo are warranted.

Acknowledgements

We would like to acknowledge Rebecca Kramer, Brianna Peckich, and Spencer Yingling for their contributions to this work.

Author Contributions

M.H. and P.A.W.-E. participated in research design; M.H., K.H., L.G., T.D., E.B., and P.A.W.-E. conducted experiments; M.H., K.H., L.G., T.D., E.B., and P.A.W.-E. performed data analysis; and M.H. and P.A.W.-E. wrote or contributed to the writing of the manuscript.

ORCID iDs

Mahmud Hasan https://orcid.org/0000-0003-0192-6166
Paula A Witt-Enderby https://orcid.org/0000-0002-1844-4457

REFERENCES

1. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304:1684-1692.
2. Rossoouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
3. Dodd BR, Bondi CD, Hasan M, et al. Co-administering melatonin with an estradiol-progestrone menopausal hormone therapy represses mammary cancer development in a mouse model of HER2-positive breast cancer. Front Oncol. 2019;9:525.
4. Kuttaraj P, Zabor P, Buseberg D, et al. Melatonin and breast cancer: evidences from preclinical and human studies. Crit Rev Oncol Hematol. 2012;81:133-139.
5. Hsieh MJ, Lin CW, Su SC, et al. Effects of miR-34b/miR-892a upregulation and inhibition of ABCB1/ABCB4 on melanin-induced apoptosis in VCR-resistant oral cancer cells. Mol Ther Nucleic Acids. 2020;19:877-889.
6. Kubarka P, Bedová A, Ghanbari H, et al. The potential therapeutic effect of melatonin on human ovarian cancer by inhibition of invasion and migration of cancer stem cells. Sci Rep. 2017;7:17062.
7. Cheng J, Yang H-L, Gu C-J, et al. Melatonin restrains the viability and angiogenesis of vascular endothelial cells by suppressing HF1a/RO5/VEGF. Int J Mol Med. 2019;43:949-955.
8. Suwanjang W, Abramov AY, Charrongkew P, Govitrapong P, Chetsawang B. Melatonin prevents cytosolic calcium overload, mitochondrial damage and cell death due to toxically high doses of dexamethasone-induced oxidative stress in human neuroblastoma SH-SY5Y cells. Neurochem Int. 2016;97:34-41.
9. Hasan M, Bondi CD, Buszko E, et al. Potential involvement of pErk1/2, pErk5, PrA, PrA/Pbh, β1-integrin, and Runx2 underlying morphogenic and anti-cancer actions of novel melatonin, estradiol, progestrone hormone therapy in HER2/neu mouse mammary Cancer Biomark. 2019 (in preparation).
10. Seyedzadeh M, McDonald L, Morris JS, Cameron ER, Blyth K. Runx2 in mammary gland development and breast cancer. J Cell Physiol. 2015;228:1137-1142.
11. Chakrabarti R, Hwang J, Anders Blanoce M, et al. Elfs5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol. 2012;14:1212-1222.
12. Draw BA, Burow ME, Beckman BS. Mek5/Erk5 pathway: the first fifteen years. Biochim Biophys Acta. 2012;1825:37-48.
13. Whyte J, Bergin O, Bianchi A, McNally S, Martin F. Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res. 2009;11:209.
14. Lahlou H, Muller WJ. Beta1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer. Breast Cancer Res. 2011;13:229.
15. Tan W, Zhang W, Strasser A, et al. Fibroblast-recruited, tumor-infiltrating CD4+ T cells stimulate mammary cancer metastasis through RANKL–RANK signalling. Nature. 2011;474:548-553.
16. Gomez N, Erazo T, Lizcano JM. Erk5 and cell proliferation: nuclear localization is what matters. Front Cell Dev Biol. 2016;4:105.
17. Dolcet X, Llobera D, Pallares J, Matias-Guiu X. NF-κβ in development and progression of human cancer. Virchows Arch. 2005;446:475-482.
18. Yao K, Carin M. NF-kappaB mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia. 2003;8:215-223.
19. Grant SG, Melan MA, Latinner JI, Witt-Enderby PA. Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol Med. 2009;11:e5.
20. Witt-Enderby PA, Slater JP, Johnson NA, et al. Effects of bone by the light/dark cycle and chronic treatment with melatonin and/or hormone replacement therapy in intact female. J Pineal Res. 2012;53:374-384.
21. Witt-Enderby PA, Dubocovich ML. Characterization and regulation of the human ML1A melatonin receptor stably expressed in Chinese hamster ovary cells. Mol Pharmacol. 1996;50:166-174.
22. Suofu Y, Li W, Jean-Alphonse FG, et al. Dual role of mitochondria in producing neu mouse mammary. J Pineal Res. 1999;26:120-127.
25. Chlebowski RT, Aragaki AK, Anderson GL. Menopausal hormone therapy influence on breast cancer outcomes in the Women’s Health Initiative. J Natl Compr Canc Netw. 2015;13:917-924.

26. Anderson G, Limacher MC, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.

27. Zeng Z, Jiang X, Li X, Wells A, Luo Y, Neoptolom R. Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls. PLoS ONE. 2018;13:e0197064.

28. Mao L, Summers W, Xiang S, et al. Melatonin represses metastasis in Her2-positive human breast cancer cells by suppressing RSK2 expression. Melat Clin Res. 2016;14:1159-1169.

29. Jardim-Perassi BV, Arbab AS, Ferreira LC, et al. Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. PLoS ONE. 2014;9:e85311.

30. Cos S, Sanchez-Barcelo EJ. Melatonin and mammatory pathological growth. Front Neuroendocrinol. 2000;21:133-170.

31. Jones MP, Melan MA, Witr-Enderby PA. Melatonin decreases cell proliferation and transformation in a melanoma receptor-dependent manner. Cancer Lett. 2000;151:133-143.

32. Borin TF, Arbab AS, Geladei GB, et al. Melatonin decreases breast cancer cell proliferation by modulating Rho-associated kinase protein-1 expression. J Pineal Res. 2016;60:3-15.

33. Bondy SC, Campbell A. Mechanisms underlying tumor suppressive properties of melatonin. Int J Mol Sci. 2018;19:2205.

34. Cos S, Blask DE. Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. J Pineal Res. 1994;17:25-32.

35. Girgert R, Hanf V, Emons G, Grundker C. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J Pineal Res. 2009;47:23-31.

36. Lai L, Yuan L, Cheng Q, Dong C, Mao L, Hill SM. Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines. Breast Cancer Res Treat. 2009;118:293-305.

37. Improta-Brears T, Whorton AR, Codazzi F, York JD, Meyer T, McDonnell DP. Estrogen-induced activation of mitogen-activated protein kinase kinase requires mobilization of intracellular calcium. Proc Natl Acad Sci U S A. 1999;96:4686-4691.

38. Skildum A, Faivre E, Lange CA. Progestrone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol Endocrinol. 2005;19:327-339.

39. Candanedo F, Galindo-Hernandez O, Serna-Marquez N, et al. Progestrone induces NFkB DNA binding activity through a PI3K/Akt-dependent pathway in MCF-7 breast cancer cells. Cancer Res. 2014;74:63-69.

40. Menendez-Menendez J, Martinez-Campos C, Melatonin: an anti-tumor agent in hormone-dependent cancers. Int J Endocrinol. 2018;2018:3271948.

41. Lai L, Yuan L, Cheng Q, Dong C, Mao L, Hill SM. Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines. Breast Cancer Res Treat. 2009;118:293-305.

42. Improta-Brears T, Whorton AR, Codazzi F, York JD, Meyer T, McDonnell DP. Estrogen-induced activation of mitogen-activated protein kinase kinase requires mobilization of intracellular calcium. Proc Natl Acad Sci U S A. 1999;96:4686-4691.

43. Oprea-Ilies G, Haus E, Sackett-Lundeen L, et al. Expression of melatonin receptor function. J Pineal Res. 2005;60:3-15.

44. Godwin P, Baird AM, Heavey S, Barr MP, O’Byrne KJ, Gately K. Targeting nuclear estrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. Eur J Cancer. 2006;42:1104-1112.

45. Svensson S, Jirström K, Ryden L, et al. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Melanoma Res. 2005;15:247-254.

46. Gallego-Ortega D, Oakes SR, Lee HF, Piggins CH, Ormandy CJ. ELFS, normal mammary development and the heterogeneous phenotypes of breast cancer. Future Med. 2013;2:489-498.

47. Li H, Zhou R, Jiang GQ, Xu JP. Clinical significance of RUNX2 expression in patients with non-metastases breast cancer cell line. Breast Cancer Res Treat. 2013;144:1807-1812.

48. Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM. MT1 melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mel Cell Endocrinol. 2002;192:147-156.

49. Collins A, Yuan L, Kifer TL, Cheng Q, Lai L, Hill SM. Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice. Cancer Lett. 2003;189:49-57.

50. Kadekarl AO, Andrade LN, Floetter-Winter LM, et al. MT1-melanin receptor expression increases the antiproliferative effect of melatonin on 5/91 murine melanoma cells. J Pineal Res. 2004;36:204-211.

51. Kobayashi Y, Itoh MT, Kondo H, et al. Melatonin binding sites in estrogen receptor-positive cells derived from human endometrial cancer. J Pineal Res. 2003;35:71-74.

52. Hill SM, Belancio VP, Dauchy RT, et al. Melatonin: an inhibitor of breast cancer cell invasion. Endocr Relat Cancer. 2015;22:R183-R204.

53. Mao L, Yuan L, Slakey LM, Jones FE, Burrow ME, Hill SM. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res Treat. 2010;12:R107.

54. Mueller H, Flury N, Eppenberger-Castori S, Kuenz W, David F, Eppenberger U. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer. 2000;89:384-388.

55. Pierce KL, Luttrell LM, Lefkowitz RJ. New mechanisms in heptahelical receptor signaling to mitogen-activated protein kinase cascade. Oncogene. 2001;20:1532-1539.

56. Sethi S, Radio NM, Kotlarczyk MP, et al. Determination of the minimal melatonin exposure required to induce osteoblast differentiation from human mesenchymal stem cells and these effects on downstream signaling pathways. J Pineal Res. 2010;49:222-231.

57. Bondi CD, McKeon RM, Bennett JM, et al. MT1 melatonin receptor internalization underlies melatonin-induced morphologic changes in Chinese hamster ovary cells and these processes are dependent on Gi proteins, MEK 1/2 and microtubule modulation. J Pineal Res. 2008;44:288-298.

58. Canel M, Serrels A, Frame MC, Brunton VG. E-cadherin–integrin crosstalk in cancer invasion and metastasis. J Cell Sci. 2013;126:393–401.

59. Yao ES, Zhang H, Chen YY, et al. Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 2007;67:659-664.

60. dos Santos PB, Zanetti JS, Ribeiro-Silva A, Beltrao EI. Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diag Pathol. 2012;7:104.

61. Ortiz-Lopez I, Morales-Mulia S, Ramirez-Rodriguez G, Benitez-King G. ROCK-regulated cytoskeletal dynamics participate in the inhibitory effect of melatonin on cancer migration. J Pineal Res. 2009;46:15-21.

62. Godwin P, Baird AM, Heavey S, Barr MP, O’Byrne KJ, Gately K. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol. 2013;3:420.

63. Fiers BRB, Mencalha AL, Ferreira GM, et al. NF-kappaB is involved in the regulation of EMT genes in breast cancer cells. Future Med Chem. 2008;4:288-298.

64. Canal M, Serrels A, Frame MC, Brunton VG. E-cadherin–integrin crosstalk in cancer invasion and metastasis. J Cell Sci. 2013;126:393–401.

65. Yao ES, Zhang H, Chen YY, et al. Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 2007;67:659-664.

66. dos Santos PB, Zanetti JS, Ribeiro-Silva A, Beltrao EI. Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diag Pathol. 2012;7:104.